59083-39-5

Usage

Uses

Used in Research Applications:
4-(4-Methylphenyl)piperidine is used as a research chemical for studying the effects of psychoactive substances on the brain and their potential for abuse and addiction. Its classification as a controlled substance limits its use to scientific research and not for medical or recreational purposes.
Used in Pharmaceutical Industry:
Although not approved for medical use, 4-(4-Methylphenyl)piperidine may be used in the pharmaceutical industry for research and development of new drugs with similar mechanisms of action. Understanding its effects on neurotransmitter release could potentially contribute to the discovery of safer and more effective treatments for various conditions.
Used in Forensic Toxicology:
4-(4-Methylphenyl)piperidine may be used in forensic toxicology for the identification and analysis of substances found in biological samples, such as blood or urine, in cases of drug abuse or poisoning. Its unique chemical structure and psychoactive properties make it a target for detection in toxicological investigations.
Used in Drug Policy and Regulation:
4-(4-Methylphenyl)piperidine serves as a case study for drug policy and regulation, providing insights into the challenges of controlling the use and distribution of novel psychoactive substances. Its classification as a controlled substance and the associated legal and public health implications can inform the development of strategies to address the emerging issue of designer drugs.

InChI:InChI=1/C12H17NO/c1-14-12-4-2-10(3-5-12)11-6-8-13-9-7-11/h2-5,11,13H,6-9H2,1H3

Upstream product

• 1122-91-4 4-bromo-benzaldehyde 
• 104-87-0 4-methyl-benzaldehyde 
• 59612-76-9 3-(4-methylphenyl)pentan-1,5-dioic acid 
• 2017-88-1 ethyl (E)-2-cyano-3-p-tolylacrylate 
• 10602-01-4 p-bromobenzaldehyde 1,3-dioxolane 
• 2403-51-2 2-(4-methylphenyl)-1,3-dioxolane 
• 694-05-3 1,2,3,6-tetrahydropyridine 
• 108-88-3 toluene 

Downstream Products

• 1255390-55-6 2-(4-para-tolylpiperidin-1-yl)benzo[d]oxazole 
• 1246082-89-2 6-(2-(4-p-tolylpiperidin-1-yl)ethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 1027354-92-2 (3-amino-4-methyl-phenyl)-[4-(4-methylphenyl)-1-piperidyl]methanone 
• 180157-54-4 (2S)-(-)-1-(4-indolyloxy)-3-(4-(4-methylphenyl)piperidin-1-yl)-2-propanol ethanedioate 

Relevant academic research and scientific papers

20-HETE FORMATION INHIBITORS

This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.

AZABENZIMIDAZOLYL COMPOUNDS

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Synthesis and binding affinities of methylvesamicol analogs for the acetylcholine transporter and sigma receptor

We synthesized methylvesamicol analogs 13-16 and investigated the binding characteristics of 2-[4-phenylpiperidino]cyclohexanol (vesamicol) and methylvesamicol analogs 13-16, with a methyl group introduced into the 4-phenylpiperidine moiety, to sigma receptors (σ-1, σ-2) and to vesicular acetylcholine transporters (VAChT) in membranes of the rat brain and liver. In competitive inhibition studies, (-)-o-methylvesamicol [(-)-OMV] (13) (Ki = 6.7 nM), as well as (-)-vesamicol (Ki = 4.4 nM), had a high affinity for VAChT. (+)-p-Methylvesamicol [(+)-PMV] (16) (Ki = 3.0 nM), as well as SA4503 (Ki = 4.4 nM), reported as a σ-1 mapping agent for positron emission tomography (PET), had a high affinity for the σ-1 receptor. The binding affinity of (+)-PMV (16) for the σ-1 receptor (Ki = 3.0 nM) was about 13 times higher than that for the sigma-2 (σ-2) receptor (Ki = 40.7 nM). (+)-PMV (16) (K i = 199 nM) had a much lower affinity for VAChT than SA4503 (K i = 50.2 nM) and haloperidol (Ki = 41.4 nM). These results showed that the binding characteristics of (-)-OMV (13) to VAChT were similar to those of (-)-vesamicol and that (+)-PMV (16) bound to the σ-1 receptor with high affinity. In conclusion, (-)-OMV (13) and (+)-PMV (16), which had a suitable structure, with a methyl group for labeling with 11C, may become not only a new VAChT ligand and a new type of σ receptor ligand, respectively, but may also become a new target compound of VAChT and the σ-1 receptor radioligand for PET, respectively.

Superacid-catalyzed preparation of aryl-substituted piperidines via dicationic electrophiles

The electrophilic chemistry of 1,2,3,6-tetrahydropyridines has been studied in the Bronsted superacid, CF3SO3H (triflic acid). The 1,2,3,6-tetrahydropyridines react with arenes to give aryl-substituted piperidines. It is proposed tha